Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PRAPTI A PATEL

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1417179391
CMS profile
1086689
Location
DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$5,433.31

9 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $4,000.00 1
Travel and Lodging $1,342.80 4
Food and Beverage $70.46 3
Education $20.05 1

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Agios Pharmaceuticals, Inc. $5,413.26 8
PFIZER INC. $20.05 1

Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PRAPTI A PATEL

NPI 1417179391 · CMS profile ID 1086689

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1417179391?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PRAPTI A PATEL, NPI 1417179391, CMS profile ID 1086689. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1417179391?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). PRAPTI A PATEL, NPI 1417179391, CMS profile ID 1086689. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1417179391?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
PRAPTI A PATEL, NPI 1417179391, CMS profile ID 1086689, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1417179391?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

9 matching records · $5,433.31 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 9 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–9 of 9.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Agios Pharmaceuticals, Inc. $43.7911/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701355677 CMS
Agios Pharmaceuticals, Inc. $26.8711/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701355679 CMS
Agios Pharmaceuticals, Inc. $4,000.0010/31/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701355675 CMS
Agios Pharmaceuticals, Inc. $353.6510/18/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701355669 CMS
Agios Pharmaceuticals, Inc. $16.9810/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701355671 CMS
Agios Pharmaceuticals, Inc. $26.6110/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701355673 CMS
Agios Pharmaceuticals, Inc. $288.3310/17/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701355665 CMS
Agios Pharmaceuticals, Inc. $657.0310/17/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701355667 CMS
PFIZER INC. $20.0507/15/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672372945 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $5,433.31 9
PY2020 $13,639.41 13
PY2021 $5,226.42 5
PY2022 $3,872.75 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022
Generated from
OP_DTL_GNRL_PGYR2022_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,500.00 1
PY2024 Principal investigator $7,162.12 1
PY2023 Principal investigator $840,129.23 6
PY2022 Principal investigator $1,052,521.66 20
PY2021 Principal investigator $5,596,160.44 47
PY2020 Principal investigator $671,832.10 66
PY2019 Principal investigator $2,060,337.42 43

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

66 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Astellas Pharma Global Development $15,241.80 12/24/2020 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
PHASE 1/2 STUDY OF ASP2215 (GILTERITINIB) COMBINED WITH ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR TREATMENT REFRACTORY FLT3 MUTATED ACUTE MYELOID LEUKEMIA (AML) No dispute reported 06/30/2026 721323299
Principal investigator 1 Agios Pharmaceuticals, Inc. $20,632.30 12/23/2020 Covered Recipient Teaching Hospital
Ut Southwestern Med Ctr-Zale Lipshy
A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation No dispute reported 06/30/2026 752075011
Principal investigator 1 Agios Pharmaceuticals, Inc. $2,307.50 12/18/2020 Covered Recipient Teaching Hospital
Ut Southwestern Med Ctr-Zale Lipshy
A Phase I, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2 Mutation No dispute reported 06/30/2026 752075013
Principal investigator 1 Celgene Corporation $1,500.00 12/18/2020 Non-covered Recipient Entity
University Of Texas Southwestern
Phase IIA AG-221-AML-005 (BMS Study Number: CA067-P12) No dispute reported 06/30/2026 736449059
Principal investigator 1 Astellas Pharma Global Development $3,056.55 11/26/2020 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
PHASE 1/2 STUDY OF ASP2215 (GILTERITINIB) COMBINED WITH ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR TREATMENT REFRACTORY FLT3 MUTATED ACUTE MYELOID LEUKEMIA (AML) No dispute reported 06/30/2026 721323125
Principal investigator 1 Celgene Corporation $1,500.00 11/23/2020 Covered Recipient Teaching Hospital
Ut Southwestern Med Ctr-Zale Lipshy
PhIII Azacitidine AML Quazar CC-486-AML-001 No dispute reported 06/30/2026 736444673
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,084.59 11/18/2020 Non-covered Recipient Entity
UT SOUTHWESTERN MEDICAL CENTER
A PHASE 3, RANDOMIZED, CONTROLLED, OPEN-LABEL, CLINICAL STUDY OF PEVONEDISTAT PLUS AZACITIDINE VERSUS SINGLE-AGENT AZACITIDINE AS FIRST-LINE TREATMENT FOR PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES, CHRONIC MYELOMONOCYTIC LEUKEMIA, OR LOW-BLAST ACUTE MYELOGENOUS LEUKEMIA No dispute reported 06/30/2026 737092555
Principal investigator 1 Astellas Pharma Global Development $15,419.30 11/05/2020 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
PHASE 1/2 STUDY OF ASP2215 (GILTERITINIB) COMBINED WITH ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR TREATMENT REFRACTORY FLT3 MUTATED ACUTE MYELOID LEUKEMIA (AML) No dispute reported 06/30/2026 721322983
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,000.00 11/04/2020 Non-covered Recipient Entity
UT SOUTHWESTERN MEDICAL CENTER
A PHASE 3, RANDOMIZED, CONTROLLED, OPEN-LABEL, CLINICAL STUDY OF PEVONEDISTAT PLUS AZACITIDINE VERSUS SINGLE-AGENT AZACITIDINE AS FIRST-LINE TREATMENT FOR PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES, CHRONIC MYELOMONOCYTIC LEUKEMIA, OR LOW-BLAST ACUTE MYELOGENOUS LEUKEMIA No dispute reported 06/30/2026 737092045
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $500.00 11/04/2020 Non-covered Recipient Entity
UT SOUTHWESTERN MEDICAL CENTER
A PHASE 3, RANDOMIZED, CONTROLLED, OPEN-LABEL, CLINICAL STUDY OF PEVONEDISTAT PLUS AZACITIDINE VERSUS SINGLE-AGENT AZACITIDINE AS FIRST-LINE TREATMENT FOR PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES, CHRONIC MYELOMONOCYTIC LEUKEMIA, OR LOW-BLAST ACUTE MYELOGENOUS LEUKEMIA No dispute reported 06/30/2026 737092047
Principal investigator 1 AbbVie Inc. $328.00 11/03/2020 Non-covered Recipient Entity
UT SOUTHWESTERN MEDICAL CENTER AT DALLAS
A18-875 No dispute reported 06/30/2026 721194203
Principal investigator 1 AbbVie Inc. $1,639.04 11/03/2020 Non-covered Recipient Entity
UT SOUTHWESTERN MEDICAL CENTER AT DALLAS
A18-875 No dispute reported 06/30/2026 721194205
Principal investigator 1 AbbVie Inc. $61,464.00 11/03/2020 Non-covered Recipient Entity
UT SOUTHWESTERN MEDICAL CENTER AT DALLAS
A18-875 No dispute reported 06/30/2026 721194207
Principal investigator 1 Otsuka Pharmaceutical Co., Ltd. $2,456.98 10/30/2020 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A PHASE 3, RANDOMIZED, OPEN-LABEL, CORSSOVER STUDY OF ASTX727 (CEDAZURIDINE AND DECITABINE FIXED-DOSE COMBINATION) VERSUS IV DECITABINE IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES (MDS) AND CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) No dispute reported 06/30/2026 753031669
Principal investigator 1 AbbVie Inc. $11,473.28 10/22/2020 Non-covered Recipient Entity
UT SOUTHWESTERN MEDICAL CENTER AT DALLAS
A18-875 No dispute reported 06/30/2026 721191905
Principal investigator 1 Boehringer Ingelheim International GmbH $1,473.12 10/08/2020 Non-covered Recipient Entity
Zale Lipshy University Hospital Main Pharmacy
BAML-16-001-S2/BI 836858 with 5-Aza No dispute reported 06/30/2026 749903425
Principal investigator 1 AbbVie Inc. $2,868.32 10/06/2020 Non-covered Recipient Entity
UT SOUTHWESTERN MEDICAL CENTER AT DALLAS
A18-875 No dispute reported 06/30/2026 721190071
Principal investigator 1 AbbVie Inc. $3,278.08 09/30/2020 Non-covered Recipient Entity
UT SOUTHWESTERN MEDICAL CENTER AT DALLAS
A18-875 No dispute reported 06/30/2026 721189089
Principal investigator 1 Otsuka Pharmaceutical Co., Ltd. $2,456.98 09/27/2020 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A PHASE 3, RANDOMIZED, OPEN-LABEL, CORSSOVER STUDY OF ASTX727 (CEDAZURIDINE AND DECITABINE FIXED-DOSE COMBINATION) VERSUS IV DECITABINE IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES (MDS) AND CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) No dispute reported 06/30/2026 753031587
Principal investigator 1 Otsuka Pharmaceutical Co., Ltd. $26,248.00 09/24/2020 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
AN OPEN-LABEL, MULTICENTER, EXTENSION STUDY FOR SUBJECTS WHO PARTICIPATED IN PRIOR CLINICAL STUDIES OF ASTX727 (STANDARD DOSE) No dispute reported 06/30/2026 753031571
Principal investigator 1 AbbVie Inc. $24,585.60 09/22/2020 Non-covered Recipient Entity
UT SOUTHWESTERN MEDICAL CENTER AT DALLAS
A18-875 No dispute reported 06/30/2026 721186429
Principal investigator 1 Agios Pharmaceuticals, Inc. $260.00 09/18/2020 Covered Recipient Teaching Hospital
Ut Southwestern Med Ctr-Zale Lipshy
A Phase I, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2 Mutation No dispute reported 06/30/2026 752074357
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $15,855.84 09/04/2020 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS
A PHASE 3, RANDOMIZED, CONTROLLED, OPEN-LABEL, CLINICAL STUDY OF PEVONEDISTAT PLUS AZACITIDINE VERSUS SINGLE-AGENT AZACITIDINE AS FIRST-LINE TREATMENT FOR PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES, CHRONIC MYELOMONOCYTIC LEUKEMIA, OR LOW-BLAST ACUTE MYELOGENOUS LEUKEMIA No dispute reported 06/30/2026 737087599
Principal investigator 1 AbbVie Inc. $164.00 08/31/2020 Non-covered Recipient Entity
UT SOUTHWESTERN MEDICAL CENTER AT DALLAS
A18-875 No dispute reported 06/30/2026 721184167
Principal investigator 1 AbbVie Inc. $409.76 08/31/2020 Non-covered Recipient Entity
UT SOUTHWESTERN MEDICAL CENTER AT DALLAS
A18-875 No dispute reported 06/30/2026 721184169
Principal investigator 1 AbbVie Inc. $49,171.20 08/31/2020 Non-covered Recipient Entity
UT SOUTHWESTERN MEDICAL CENTER AT DALLAS
A18-875 No dispute reported 06/30/2026 721184171
Principal investigator 1 APTEVO THERAPEUTICS INC $62,558.00 08/27/2020 Non-covered Recipient Entity
UNIVERSITY OF TEXAS SOUTHWESTERN
APVO436 No dispute reported 06/30/2026 752946131
Principal investigator 1 Otsuka Pharmaceutical Co., Ltd. $4,913.96 08/14/2020 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A PHASE 3, RANDOMIZED, OPEN-LABEL, CORSSOVER STUDY OF ASTX727 (CEDAZURIDINE AND DECITABINE FIXED-DOSE COMBINATION) VERSUS IV DECITABINE IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES (MDS) AND CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) No dispute reported 06/30/2026 753031459
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,220.00 08/14/2020 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS
A PHASE 3, RANDOMIZED, CONTROLLED, OPEN-LABEL, CLINICAL STUDY OF PEVONEDISTAT PLUS AZACITIDINE VERSUS SINGLE-AGENT AZACITIDINE AS FIRST-LINE TREATMENT FOR PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES, CHRONIC MYELOMONOCYTIC LEUKEMIA, OR LOW-BLAST ACUTE MYELOGENOUS LEUKEMIA No dispute reported 06/30/2026 737086543
Principal investigator 1 APTEVO THERAPEUTICS INC $13,390.00 08/10/2020 Non-covered Recipient Entity
UNIVERSITY OF TEXAS SOUTHWESTERN
APVO436 No dispute reported 06/30/2026 752946119
Principal investigator 1 Otsuka Pharmaceutical Co., Ltd. $7,500.00 07/29/2020 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A PHASE 3, RANDOMIZED, OPEN-LABEL, CORSSOVER STUDY OF ASTX727 (CEDAZURIDINE AND DECITABINE FIXED-DOSE COMBINATION) VERSUS IV DECITABINE IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES (MDS) AND CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) No dispute reported 06/30/2026 753031389
Principal investigator 1 Astellas Pharma Global Development $12,220.00 07/02/2020 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
PHASE 1/2 STUDY OF ASP2215 (GILTERITINIB) COMBINED WITH ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR TREATMENT REFRACTORY FLT3 MUTATED ACUTE MYELOID LEUKEMIA (AML) No dispute reported 06/30/2026 721322243
Principal investigator 1 Otsuka Pharmaceutical Co., Ltd. $4,065.72 07/01/2020 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A PHASE 3, RANDOMIZED, OPEN-LABEL, CORSSOVER STUDY OF ASTX727 (CEDAZURIDINE AND DECITABINE FIXED-DOSE COMBINATION) VERSUS IV DECITABINE IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES (MDS) AND CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) No dispute reported 06/30/2026 753031291
Principal investigator 1 Agios Pharmaceuticals, Inc. $1,500.00 06/24/2020 Covered Recipient Teaching Hospital
Ut Southwestern University Hosp
A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation No dispute reported 06/30/2026 752073445
Principal investigator 1 Agios Pharmaceuticals, Inc. $4,769.00 06/24/2020 Covered Recipient Teaching Hospital
Ut Southwestern University Hosp
A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation No dispute reported 06/30/2026 752074067
Principal investigator 1 Agios Pharmaceuticals, Inc. $3,250.00 06/24/2020 Covered Recipient Teaching Hospital
Ut Southwestern University Hosp
A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation No dispute reported 06/30/2026 752075349
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,500.00 06/17/2020 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS
A PHASE 3, RANDOMIZED, CONTROLLED, OPEN-LABEL, CLINICAL STUDY OF PEVONEDISTAT PLUS AZACITIDINE VERSUS SINGLE-AGENT AZACITIDINE AS FIRST-LINE TREATMENT FOR PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES, CHRONIC MYELOMONOCYTIC LEUKEMIA, OR LOW-BLAST ACUTE MYELOGENOUS LEUKEMIA No dispute reported 06/30/2026 737083493
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $132.60 06/03/2020 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS
A PHASE 3, RANDOMIZED, CONTROLLED, OPEN-LABEL, CLINICAL STUDY OF PEVONEDISTAT PLUS AZACITIDINE VERSUS SINGLE-AGENT AZACITIDINE AS FIRST-LINE TREATMENT FOR PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES, CHRONIC MYELOMONOCYTIC LEUKEMIA, OR LOW-BLAST ACUTE MYELOGENOUS LEUKEMIA No dispute reported 06/30/2026 737082463
Principal investigator 1 Agios Pharmaceuticals, Inc. $21,658.00 06/01/2020 Covered Recipient Teaching Hospital
Ut Southwestern Med Ctr-Zale Lipshy
A Phase I, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2 Mutation No dispute reported 06/30/2026 752073139
Principal investigator 1 APTEVO THERAPEUTICS INC $2,591.50 05/28/2020 Non-covered Recipient Entity
UNIVERSITY OF TEXAS SOUTHWESTERN
APVO436 No dispute reported 06/30/2026 752946085
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,354.20 05/22/2020 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS
A PHASE 3, RANDOMIZED, CONTROLLED, OPEN-LABEL, CLINICAL STUDY OF PEVONEDISTAT PLUS AZACITIDINE VERSUS SINGLE-AGENT AZACITIDINE AS FIRST-LINE TREATMENT FOR PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES, CHRONIC MYELOMONOCYTIC LEUKEMIA, OR LOW-BLAST ACUTE MYELOGENOUS LEUKEMIA No dispute reported 06/30/2026 737081851
Principal investigator 1 Otsuka Pharmaceutical Co., Ltd. $200.00 05/19/2020 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A PHASE 3, RANDOMIZED, OPEN-LABEL, CORSSOVER STUDY OF ASTX727 (CEDAZURIDINE AND DECITABINE FIXED-DOSE COMBINATION) VERSUS IV DECITABINE IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES (MDS) AND CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) No dispute reported 06/30/2026 753031187
Principal investigator 1 Astellas Pharma Global Development $1,500.00 05/14/2020 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
PHASE 1/2 STUDY OF ASP2215 (GILTERITINIB) COMBINED WITH ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR TREATMENT REFRACTORY FLT3 MUTATED ACUTE MYELOID LEUKEMIA (AML) No dispute reported 06/30/2026 721321941
Principal investigator 1 Astellas Pharma Global Development $23,640.00 05/07/2020 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
PHASE 1/2 STUDY OF ASP2215 (GILTERITINIB) COMBINED WITH ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR TREATMENT REFRACTORY FLT3 MUTATED ACUTE MYELOID LEUKEMIA (AML) No dispute reported 06/30/2026 721321863
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,575.70 05/01/2020 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS
A PHASE 3, RANDOMIZED, CONTROLLED, OPEN-LABEL, CLINICAL STUDY OF PEVONEDISTAT PLUS AZACITIDINE VERSUS SINGLE-AGENT AZACITIDINE AS FIRST-LINE TREATMENT FOR PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES, CHRONIC MYELOMONOCYTIC LEUKEMIA, OR LOW-BLAST ACUTE MYELOGENOUS LEUKEMIA No dispute reported 06/30/2026 737078169
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $47,357.00 04/17/2020 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS
A PHASE 3, RANDOMIZED, CONTROLLED, OPEN-LABEL, CLINICAL STUDY OF PEVONEDISTAT PLUS AZACITIDINE VERSUS SINGLE-AGENT AZACITIDINE AS FIRST-LINE TREATMENT FOR PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES, CHRONIC MYELOMONOCYTIC LEUKEMIA, OR LOW-BLAST ACUTE MYELOGENOUS LEUKEMIA No dispute reported 06/30/2026 737077583
Principal investigator 1 Otsuka Pharmaceutical Co., Ltd. $16,654.84 04/08/2020 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A PHASE 3, RANDOMIZED, OPEN-LABEL, CORSSOVER STUDY OF ASTX727 (CEDAZURIDINE AND DECITABINE FIXED-DOSE COMBINATION) VERSUS IV DECITABINE IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES (MDS) AND CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) No dispute reported 06/30/2026 753031085
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $130.00 04/08/2020 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS
A PHASE 3, RANDOMIZED, CONTROLLED, OPEN-LABEL, CLINICAL STUDY OF PEVONEDISTAT PLUS AZACITIDINE VERSUS SINGLE-AGENT AZACITIDINE AS FIRST-LINE TREATMENT FOR PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES, CHRONIC MYELOMONOCYTIC LEUKEMIA, OR LOW-BLAST ACUTE MYELOGENOUS LEUKEMIA No dispute reported 06/30/2026 737076393
Principal investigator 1 Otsuka Pharmaceutical Co., Ltd. $550.00 03/26/2020 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A PHASE 3, RANDOMIZED, OPEN-LABEL, CORSSOVER STUDY OF ASTX727 (CEDAZURIDINE AND DECITABINE FIXED-DOSE COMBINATION) VERSUS IV DECITABINE IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES (MDS) AND CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) No dispute reported 06/30/2026 753031029
Principal investigator 1 Agios Pharmaceuticals, Inc. $10,205.00 03/20/2020 Covered Recipient Teaching Hospital
Ut Southwestern Med Ctr-Zale Lipshy
Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation No dispute reported 06/30/2026 752073759
Principal investigator 1 Agios Pharmaceuticals, Inc. $1,500.00 03/18/2020 Covered Recipient Teaching Hospital
Ut Southwestern Med Ctr-Zale Lipshy
Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation No dispute reported 06/30/2026 752073443
Principal investigator 1 Agios Pharmaceuticals, Inc. $5,450.00 03/11/2020 Covered Recipient Teaching Hospital
Ut Southwestern Med Ctr-Zale Lipshy
Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation No dispute reported 06/30/2026 752073137
Principal investigator 1 Otsuka Pharmaceutical Co., Ltd. $200.00 02/13/2020 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A PHASE 3, RANDOMIZED, OPEN-LABEL, CORSSOVER STUDY OF ASTX727 (CEDAZURIDINE AND DECITABINE FIXED-DOSE COMBINATION) VERSUS IV DECITABINE IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES (MDS) AND CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) No dispute reported 06/30/2026 753030959
Principal investigator 1 Celgene Corporation $7,332.00 02/05/2020 Non-covered Recipient Entity
The University Of Texas Southwestern Medical Center
Phase IIA AG-221-AML-005 (BMS Study Number: CA067-P12) No dispute reported 06/30/2026 736445849
Principal investigator 1 Agios Pharmaceuticals, Inc. $15,990.00 01/28/2020 Covered Recipient Teaching Hospital
Ut Southwestern University Hosp
A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation No dispute reported 06/30/2026 752073439
Principal investigator 1 Agios Pharmaceuticals, Inc. $5,785.00 01/28/2020 Covered Recipient Teaching Hospital
Ut Southwestern University Hosp
A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation No dispute reported 06/30/2026 752075009
Principal investigator 1 Otsuka Pharmaceutical Co., Ltd. $7,663.45 01/24/2020 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A PHASE 3, RANDOMIZED, OPEN-LABEL, CORSSOVER STUDY OF ASTX727 (CEDAZURIDINE AND DECITABINE FIXED-DOSE COMBINATION) VERSUS IV DECITABINE IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES (MDS) AND CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) No dispute reported 06/30/2026 753030883
Principal investigator 1 Agios Pharmaceuticals, Inc. $16,445.01 01/22/2020 Covered Recipient Teaching Hospital
Ut Southwestern Med Ctr-Zale Lipshy
Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation No dispute reported 06/30/2026 752073441
Principal investigator 1 Celgene Corporation $390.00 01/22/2020 Non-covered Recipient Entity
The University Of Texas Southwestern Medical Center
Phase IIA AG-221-AML-005 (BMS Study Number: CA067-P12) No dispute reported 06/30/2026 736445033
Principal investigator 1 Celgene Corporation $40,201.00 01/22/2020 Non-covered Recipient Entity
University Of Texas Southwestern Medical School
Phase IIA AG-221-AML-005 (BMS Study Number: CA067-P12) No dispute reported 06/30/2026 736450281
Principal investigator 1 APTEVO THERAPEUTICS INC $27,865.00 01/21/2020 Non-covered Recipient Entity
UNIVERSITY OF TEXAS SOUTHWESTERN
APVO436 No dispute reported 06/30/2026 752946081
Principal investigator 1 Agios Pharmaceuticals, Inc. $1,430.00 01/21/2020 Covered Recipient Teaching Hospital
Ut Southwestern University Hosp
A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation No dispute reported 06/30/2026 752074687
Principal investigator 1 Agios Pharmaceuticals, Inc. $845.00 01/21/2020 Covered Recipient Teaching Hospital
Ut Southwestern University Hosp
A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation No dispute reported 06/30/2026 752075347
Principal investigator 1 Celgene Corporation $4,145.88 01/20/2020 Non-covered Recipient Entity
Ut Southwestern Medical Center At Dallas
Phase IIA AG-221-AML-005 (BMS Study Number: CA067-P12) No dispute reported 06/30/2026 736447593
Principal investigator 1 Agios Pharmaceuticals, Inc. $390.00 01/15/2020 Covered Recipient Teaching Hospital
Ut Southwestern University Hosp
A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation No dispute reported 06/30/2026 752074355
Principal investigator 1 Agios Pharmaceuticals, Inc. $390.00 01/15/2020 Covered Recipient Teaching Hospital
Ut Southwestern University Hosp
A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation No dispute reported 06/30/2026 752075007